<DOC>
	<DOCNO>NCT01083693</DOCNO>
	<brief_summary>The aim post-marketing observational study obtain data evaluation quality life outcome HUMIRA速 routine clinical use patient Rheumatoid Arthritis ( RA ) , Psoriatic Arthritis ( PsA ) Ankylosing Spondylitis ( AS ) unsustainable clinical response disease modify antirheumatic drug ( DMARD ) biological disease modify antirheumatic drug ( BDMARD ) . Treatment strategy moderate severe rheumatoid arthritis , psoriatic arthritis severe active ankylose spondylitis commonly consist introduce biologics conventional disease modify antirheumatic drug non steroidal antiinflammatory drug fail . Although biologic disease modify antirheumatic drug generally well-tolerated , intolerance may develop efficacy may diminish , time another biologic disease modify antirheumatic drug might consider . This study shall evaluate quality life outcome HUMIRA速 , give conventional disease modify antirheumatic drug non antiinflammatory drug failure biological disease modify antirheumatic drug failure . Failure context mean primary secondary loss efficacy intolerance initial agent .</brief_summary>
	<brief_title>Quality Life Outcomes HUMIRA Rheumatoid Arthritis ( RA ) , Psoriatic Arthritis ( PsA ) , Ankylosing Spondylitis ( AS ) After Unsustainable Response Biologicals Disease Modifying Antirheumatic Drugs</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Patients age great equal 18 Patients must fulfill international national guideline use BDMARD RA , PsA AS ( Chest Xray purify protein derivative ( PPD ) skin test negative tuberculosis ) . In addition one follow criterion must fulfil : unsatisfactory DMARD response define failure treatment least two DMARDs include Methotrexate patient RA PsA unsatisfactory NSAID response patient AS unsatisfactory response prior BDMARDs ( case patient must receive BDMARDs least 12 week visit 1 ) patient RA PsA AS . Patients meet contraindication outline late version Humira syringe速 Summary Product Characteristics ( SmPC ) Humira Pen速 SmPC Patients participate another study clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Monoclonals</keyword>
	<keyword>Antibodies</keyword>
	<keyword>Ankylosing Spondylitis</keyword>
	<keyword>Antirheumatic Agents</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>psoriatic arthritis</keyword>
</DOC>